Nearly nine in ten adults taking oral semaglutide reported meaningful quality-of-life gains within three months, according to real-world data unveiled at ObesityWeek 2026 in Washington, D.C.
Novo Nordisk (NYSE: NVO) presented findings from two large retrospective cohort analyses, SIGNAL and OCTANE, drawing on de-identified records from the Ro telehealth platform to examine a phenomenon called food noise.
Food noise, defined as persistent, intrusive and unwanted thoughts about food, is an emerging focus in obesity research that goes beyond conventional weight-loss metrics.
The OCTANE study followed 7,669 adults who began oral semaglutide between January and February 2026, tracking self-reported food noise using a validated seven-item questionnaire.
Over three months, average food noise scores fell roughly 25%, dropping from 2.8 to 2.1 on the RAID-FN scale, a statistically significant change with a p-value below 0.001.
At the three-month mark, 86.4% of participants reported at least one treatment improvement, spanning better-fitting clothing at 67.5%, healthier eating at 51.6%, and improved mood at 21.7%.
Fewer alcohol cravings were noted by 18.8% of participants and better sleep by 18.6%, suggesting semaglutide’s influence may extend well into daily behavioral patterns.
The larger SIGNAL study enrolled 26,213 treatment-naïve adults on semaglutide injection, tracking them for up to six months with an adjusted mean baseline food noise score of 2.72.
Scores declined measurably within the first month by an adjusted mean of -0.42 points, and continued falling through six months, reaching a cumulative change from baseline of -0.72 points.
Louis J. Aronne, MD, Director of the Comprehensive Weight Control Center at Weill Cornell Medicine and a co-author of both studies, underscored the everyday burden these findings address: “Patients at our center often describe persistent and intrusive thoughts about food, and that managing those thoughts can take a toll on their day-to-day lives.”
Aronne added that “the SIGNAL and OCTANE findings showed that semaglutide injection and oral semaglutide were associated with early reductions in food noise in real-world studies,” while calling for further research to clarify clinical relevance.
Michelle Skinner Moore, PharmD, MBA, interim head of clinical development, medical and regulatory affairs at Novo, framed the research within the company’s broader scientific ambitions, saying Novo is “working to advance the science of obesity and broaden understanding beyond changes on the scale.”
Both analyses are observational in nature, meaning they can identify associations with semaglutide use but cannot establish a direct causal relationship between the drug and reduced food noise.
Researchers flagged several limitations, including potential self-reporting bias, variable data completeness within routine telehealth care, and restricted generalizability to populations beyond those studied.
Wegovy carries a Boxed Warning regarding possible thyroid tumors, including cancer, and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Common side effects include nausea, diarrhea, vomiting, constipation, dizziness, headache, fatigue, and hair loss, among others.
The conference presentations mark a growing effort within obesity medicine to quantify patient-centered outcomes that clinical trials have traditionally not captured, as GLP-1 medicines reach broader populations worldwide.